Lupin's Strategic Leap: Revolutionizing Drug Delivery with PrecisionSphere

Lupin launches a strategic partnership program to expand its PrecisionSphere long-acting injectable platform. With FDA approval, the platform is ready for commercial use, promising improved drug delivery consistency. Lupin aims to collaborate globally, enhancing drug lifecycles and addressing compliance issues in pharmaceuticals.

Lupin, a leading pharmaceutical company, has announced a strategic partnership initiative to broaden the reach of its subsidiary Nanomi BV's long-acting injectable platform, PrecisionSphere.

PrecisionSphere has demonstrated efficacy and safety in drug delivery. Recent approval by the US FDA marks its readiness for commercial deployment. The partnership program seeks collaboration with companies interested in extending product lifecycles, particularly those that could benefit from extended drug formulations.

Fabrice Egros, Lupin's President of Corporate Development, highlighted the program's potential to expand patient access to advanced treatments. PrecisionSphere addresses compliance issues in pharmaceuticals by enabling consistent particle sizes and drug concentrations, optimizing treatment outcomes. Shares were trading at Rs 1,952.25 on Thursday.

(With inputs from agencies.)